

July 23, 2012



Mexico Grants Quick-Med Technologies Additional NIMBUS(R) Patent

Further Expands NIMBUS' International Intellectual Property Protection

GAINESVILLE, FL -- (MARKETWIRE) -- 07/23/12 -- Quick-Med Technologies, Inc. (PINKSHEETS: QMDT) (OTCQB: QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the patent office of Mexico, Instituto Mexicano de la Propiedad Industrial (IMPI), has issued a new patent that expands the international intellectual property coverage of Quick-Med's NIMBUS[®] technology.

Mexico patent No. 297,242 is titled "Method of Attaching an Antimicrobial Cationic Polyelectrolyte to the Surface of a Substrate." It remains in effect until August 22, 2026. Similar patents have been granted in the United States, Australia, and South Africa and are pending in Canada, China, Europe, India, and Japan.

The new patent covers the method of production that non-leachably bonds NIMBUS antimicrobials to various treated substrates. It addresses the process of attaching members of the NIMBUS family of antimicrobials to substrates that are whole or in part cellulosic or any of a list of other substrates including such polymerics as polyurethane, polyester, nylon and acrylics, as well as silk, linen, rubber, alginates and collagen among many others. These are materials that are commonly used in textile and medical products, filters, absorbent products, and packaging.

"Our non-leachable bonding of the antimicrobial agent distinguishes NIMBUS from other antimicrobial materials which require release of the active agent in order to function," said Dr. Jerry Olderman, Quick-Med's vice president of Research & Development. "This patent covers the process of treating materials such that they become permanent barriers to the

transmission of microorganisms."

While NIMBUS antimicrobials remain at full strength, the active agent in most other antimicrobial technologies is depleted gradually while in use. These other antimicrobials carry the risk of irritation or interference with healing in products such as wound dressings and textile applications in which the treated material is next to or used on the skin.

The bonding of an antimicrobial to a substrate is a paradigm shift from the current state-of-the-art which fosters release of the active agent. The value of a non-leaching antimicrobial is that it does not allow depletion of the active agent which can lead to damage to human skin or tissue cells such that they can cause irritation, delay healing and possibly initiate the development of bacterial resistance.

About NIMBUS

Quick-Med's patented technology, NIMBUS, is a cutting-edge antimicrobial technology that has been custom designed for wound care and other medical applications. NIMBUS received *De Novo* FDA clearance in 2009 and has been commercialized in traditional wound care applications. It is the only non-leaching antimicrobial dressing which, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by twelve U.S. patents and patents pending and 24 foreign counterparts. Additional applications under development include advanced wound dressings, medical adhesives, catheters, and contact lenses.

About Quick-Med Technologies, Inc.

Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the consumer and healthcare markets. In addition to NIMBUS, Quick-Med's *Stay Fresh*® technology provides highly durable antimicrobial protection for laundered apparel and other textile applications and its NimbuDerm™ technology is being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.

© 2012 Quick-Med Technologies, Inc. All rights reserved. NIMBUS® and *Stay Fresh*® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.

CONTACT:

Quick-Med Technologies

J. Ladd Greeno

CEO

(888) 835.2211 Ext 102

[Email Contact](#)